Aurelien Venara1,2, Juliette Podevin1, Philippe Godeberge3, Yann Redon4, Marie-Line Barussaud5, Igor Sielezneff6, Michel Queralto7, Cecile Bourbao8, Anne Chiffoleau9, Paul A Lehur10,11. 1. Colorectal Unit, Institut des Maladies de l'Appareil Digestif (IMAD), University Hospital of Nantes, Nantes, France. 2. Department of Digestive Surgery, Angers University Hospital, Angers, France. 3. Proctology, Institut Mutualiste Montsouris, Paris, France. 4. Department of Digestive Surgery, Pôle Hospitalier Mutualiste, St Nazaire, France. 5. Department of Visceral Surgery, CHD, La Roche/Yon, France. 6. Department of General and Digestive Surgery, La Timone University Hospital, Marseilles, France. 7. Proctology - Department of Digestive Surgery, University Hospital of Toulouse, Toulouse, France. 8. Department of Digestive Surgery, University Hospital of Tours, Tours, France. 9. Office of Research, University Hospital of Nantes, Nantes, France. 10. Colorectal Unit, Institut des Maladies de l'Appareil Digestif (IMAD), University Hospital of Nantes, Nantes, France. paulantoine.lehur@chu-nantes.fr. 11. Department of Digestive and Endocrine Surgery, University Hospital of Nantes, Nantes, France. paulantoine.lehur@chu-nantes.fr.
Abstract
PURPOSE: Little is presently known on the impact of device type for Doppler-guided hemorrhoidal artery ligation/mucopexy (DGHAL) or circular stapled hemorrhoidopexy (CSH) when a surgical treatment is considered for hemorrhoidal disease (HD). In this study, we aimed to compare the outcome in terms of adverse events and recurrence rate, of patients included in the multicenter LigaLongo RCT ( ClinicalTrials.gov NCT01240772) according to the type of devices used. METHODS: In the DGHAL arm (N = 193), the procedure was done with transanal hemorrhoidal dearterialization (THD)™ (THD, Correggio, Italy) (104 patients) and with HAL-RAR™ (Agency for Medical Innovations (AMI) GmbH, Feldkirch, Austria) (89 patients). In the CSH arm (N = 184), procedure for prolapse and hemorrhoids (PPH)-03™ (Ethicon Endo-Surgery, Cincinnati OH) and hemorrhoidopexy and prolapse (HEM)™ (Covidien, Inc.) staplers were used in respectively 106 and 78 cases. Surgery-related morbidity at 90 postoperative days (POD) based on the Clavien-Dindo procedure-related complication score and clinical outcome in terms of recurrence and reoperation rate at 12 postoperative months (POM) was collected. RESULTS:Three hundred and seventy-seven patients were randomized according to HD grade. In the DGHAL arm, the number of ligations and mucopexies was higher in the AMI group (p < 0.0001); at 90 POD, the overall morbidity was similar between the two groups. In the CSH arm, donut sizes were similar; at 90 POD, the PPH group had a higher risk of postoperative grade 1 morbidity (anal urgency or incontinence) compared to the HEM group (p = 0.003). At 12 POM, no statistical difference was found between the two groups of each arm in terms of grade III recurrence or reoperation. CONCLUSION:Postoperative morbidity and outcome at 1 year were similar regardless of the type of devices used. These findings suggest that device type has little impact on HD treatment results. TRIAL REGISTRATION: clinicaltrials.gov -Identifier NCT01240772.
RCT Entities:
PURPOSE: Little is presently known on the impact of device type for Doppler-guided hemorrhoidal artery ligation/mucopexy (DGHAL) or circular stapled hemorrhoidopexy (CSH) when a surgical treatment is considered for hemorrhoidal disease (HD). In this study, we aimed to compare the outcome in terms of adverse events and recurrence rate, of patients included in the multicenter LigaLongo RCT ( ClinicalTrials.gov NCT01240772) according to the type of devices used. METHODS: In the DGHAL arm (N = 193), the procedure was done with transanal hemorrhoidal dearterialization (THD)™ (THD, Correggio, Italy) (104 patients) and with HAL-RAR™ (Agency for Medical Innovations (AMI) GmbH, Feldkirch, Austria) (89 patients). In the CSH arm (N = 184), procedure for prolapse and hemorrhoids (PPH)-03™ (Ethicon Endo-Surgery, Cincinnati OH) and hemorrhoidopexy and prolapse (HEM)™ (Covidien, Inc.) staplers were used in respectively 106 and 78 cases. Surgery-related morbidity at 90 postoperative days (POD) based on the Clavien-Dindo procedure-related complication score and clinical outcome in terms of recurrence and reoperation rate at 12 postoperative months (POM) was collected. RESULTS: Three hundred and seventy-seven patients were randomized according to HD grade. In the DGHAL arm, the number of ligations and mucopexies was higher in the AMI group (p < 0.0001); at 90 POD, the overall morbidity was similar between the two groups. In the CSH arm, donut sizes were similar; at 90 POD, the PPH group had a higher risk of postoperative grade 1 morbidity (anal urgency or incontinence) compared to the HEM group (p = 0.003). At 12 POM, no statistical difference was found between the two groups of each arm in terms of grade III recurrence or reoperation. CONCLUSION: Postoperative morbidity and outcome at 1 year were similar regardless of the type of devices used. These findings suggest that device type has little impact on HD treatment results. TRIAL REGISTRATION: clinicaltrials.gov -Identifier NCT01240772.
Authors: Steven Brown; Jim Tiernan; Katie Biggs; Daniel Hind; Neil Shephard; Mike Bradburn; Allan Wailoo; Abualbishr Alshreef; Lizzie Swaby; Angus Watson; Simon Radley; Oliver Jones; Paul Skaife; Anil Agarwal; Pasquale Giordano; Marc Lamah; Mark Cartmell; Justin Davies; Omar Faiz; Karen Nugent; Andrew Clarke; Angus MacDonald; Phillip Conaghan; Paul Ziprin; Rohit Makhija Journal: Health Technol Assess Date: 2016-11 Impact factor: 4.014
Authors: Paul A Lehur; Anne S Didnée; Jean-Luc Faucheron; Guillaume Meurette; Philippe Zerbib; Laurent Siproudhis; Béatrice Vinson-Bonnet; Anne Dubois; Christine Casa; Jean-Benoit Hardouin; Isabelle Durand-Zaleski Journal: Ann Surg Date: 2016-11 Impact factor: 12.969
Authors: Carlos Hoyuela; Fernando Carvajal; Montserrat Juvany; Daniel Troyano; Miquel Trias; Antoni Martrat; Jordi Ardid; Joan Obiols Journal: Int J Surg Date: 2016-02-10 Impact factor: 6.071
Authors: Francisco Pérez-Vicente; Antonio Arroyo; Pilar Serrano; Fernando Candela; Ana Sánchez; Rafael Calpena Journal: Int J Colorectal Dis Date: 2005-04-21 Impact factor: 2.571
Authors: Angus J M Watson; Jemma Hudson; Jessica Wood; Mary Kilonzo; Steven R Brown; Alison McDonald; John Norrie; Hanne Bruhn; Jonathan A Cook Journal: Lancet Date: 2016-10-07 Impact factor: 79.321